X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
BI-1206 is a first-in-class fully human monoclonal antibody (mAb) that targets FcγRIIB. It is being evaluated in combination with rituximab in patients with Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma.
Lead Product(s): BI-1206,Rituximab
Therapeutic Area: Oncology Product Name: BI-1206
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Recipient: BioInvent
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 05, 2024
Details:
The partnership aims for the manufacturing and advancement of iTolerance's Streptavidin-FasL (SA-FasL) fusion protein, a crucial component of the proprietary iTOL-100 platform technology towards first in human clinical study for lead program, iTOL-102.
Lead Product(s): Pralatrexate
Therapeutic Area: Oncology Product Name: Folotyn
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Acrotech Biopharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 01, 2023
Details:
Through the acquisition, CASI gains global rights to the Cleave's clinical asset, CB-5339 tosylate, an oral, second-generation, small molecule valosin-containing protein (VCP)/p97 inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndrome.
Lead Product(s): CB-5339
Therapeutic Area: Oncology Product Name: CB-5339
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Cleave Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition July 20, 2023
Details:
CB-5339 is an oral second-generation, small molecule VCP/p97 inhibitor, and is currently in Phase 1 clinical trial in patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and myeloproliferative neoplasms.
Lead Product(s): CB-5339
Therapeutic Area: Oncology Product Name: CB-5339
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cleave Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 06, 2023
Details:
CNCT19 (Inaticabtagene Autoleucel), is the first CAR-T cell therapy for the treatment of B-ALL submitted for NDA and has the potential to be the first approved domestic developed CD19 directed CAR-T therapy in China.
Lead Product(s): Inaticabtagene Autoleucel,Fludarabine Phosphate,Cyclophosphamide
Therapeutic Area: Oncology Product Name: CNCT19
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2022
Details:
BI-1206, a first-in-class fully human monoclonal antibody (mAb) that targets FcγRIIB, in combination with rituximab in patients with relapsed/refractory Non-Hodgkin's Lymphoma (NHL).
Lead Product(s): BI1206,Rituximab
Therapeutic Area: Oncology Product Name: BI1206
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: BioInvent
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2022
Details:
Under the terms of the agreement, CASI maintains exclusive US commercialization and co-marketing rights of CID-103 for the treatment, prevention, and diagnosis of autoimmune diseases, conditions, and disorders in the United States.
Lead Product(s): CID-103
Therapeutic Area: Oncology Product Name: CID-103
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: Precision Autoimmune Therapeutics
Deal Size: $21.0 million Upfront Cash: Undisclosed
Deal Type: Financing July 08, 2022
Details:
Under the terms of the agreement, CASI shall maintain the exclusive commercialization and co-marketing rights of CID-103 in autoimmune indications and book all revenue in the United States.
Lead Product(s): CID-103
Therapeutic Area: Oncology Product Name: CID-103
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Beijing Tianshi Tongda Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: $10.0 million
Deal Type: Licensing Agreement May 24, 2022
Details:
Under the terms of the agreement, China Resources Pharmaceutical Commercial Group International Trading Co., will continue to be the sole distributor for the sale of EVOMELA® (melphalan) for Injection in China.
Lead Product(s): Melphalan
Therapeutic Area: Oncology Product Name: Evomela
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Guokang Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 04, 2022
Details:
Under the terms of the agreement, Cleave and CASI will develop CB-5339 in both hematological malignancies and solid tumors, with CASI responsible for development and commercialization in China and associated markets.
Lead Product(s): CB-5339 Tosylate
Therapeutic Area: Oncology Product Name: CB-5339
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Cleave Therapeutics
Deal Size: $85.0 million Upfront Cash: $5.5 million
Deal Type: Licensing Agreement March 08, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
